Genmab CEO on legal fight with Janssen: Standing up straight and fighting for what's morally and ethically right
The trial between collaborative partners Genmab and Janssen is moving along, but according to Jan van de Winkel it's too early to conclude when a verdict will be made.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
Genmab and its CEO Jan van de Winkel will fight to the last breath in in its current dispute with US partner Janssen. At least, that is the impression you get from speaking to the Dutch bussinessman.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab spent more than DKK 1 billion in Q1
For subscribers
